Literature DB >> 30661630

Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.

Elly Stolk1, Kristina Ludwig2, Kim Rand3, Ben van Hout4, Juan Manuel Ramos-Goñi5.   

Abstract

A standardized 5-level EuroQol 5-dimensional questionnaire (EQ-5D-5L) valuation protocol was first used in national studies in the period 2012 to 2013. A set of problems encountered in this initial wave of valuation studies led to the subsequent refinement of the valuation protocol. To clarify lessons learned and how the protocol was updated when moving from version 1.0 to the current version 2.1 and 2.0, this article will (1) present the challenges faced in EQ-5D-5L valuation since 2012 and how these were resolved and (2) describe in depth a set of new challenges that have become central in currently ongoing research on how EQ-5D-5L health states should be valued and modeled.
Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Keywords:  EQ-5D-5L; discrete choice experiment; health valuation; time trade-off; utilities

Mesh:

Year:  2019        PMID: 30661630     DOI: 10.1016/j.jval.2018.05.010

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  60 in total

Review 1.  State-of-the-art: outcome assessment in adult spinal deformity.

Authors:  Jeffrey L Gum; Leah Y Carreon; Steven D Glassman
Journal:  Spine Deform       Date:  2020-10-09

2.  A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.

Authors:  Pedro L Ferreira; Patrícia Antunes; Lara N Ferreira; Luís N Pereira; Juan M Ramos-Goñi
Journal:  Qual Life Res       Date:  2019-06-14       Impact factor: 4.147

3.  EQ-5D-5L: a value set for Romania.

Authors:  Elena Olariu; Wael Mohammed; Yemi Oluboyede; Raluca Caplescu; Ileana Gabriela Niculescu-Aron; Marian Sorin Paveliu; Luke Vale
Journal:  Eur J Health Econ       Date:  2022-06-10

4.  Health state utilities for beta-thalassemia: a time trade-off study.

Authors:  Antony P Martin; Enrico Ferri Grazzi; Claudia Mighiu; Manoj Chevli; Farrukh Shah; Louise Maher; Anum Shaikh; Aliah Sagar; Hayley Hubberstey; Bethany Franks; Juan M Ramos-Goñi; Mark Oppe; Derek Tang
Journal:  Eur J Health Econ       Date:  2022-03-26

5.  A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets.

Authors:  Donna Rowen; Clara Mukuria; Emily McDool
Journal:  Pharmacoeconomics       Date:  2022-07-13       Impact factor: 4.558

6.  Valuing EQ-5D-Y: the current state of play.

Authors:  N Devlin; T Pan; S Kreimeier; J Verstraete; E Stolk; K Rand; M Herdman
Journal:  Health Qual Life Outcomes       Date:  2022-07-06       Impact factor: 3.077

7.  Cross-sectional validation of the PROMIS-Preference scoring system by its association with social determinants of health.

Authors:  Janel Hanmer
Journal:  Qual Life Res       Date:  2020-11-08       Impact factor: 4.147

8.  Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.

Authors:  Takeru Shiroiwa; Shunya Ikeda; Shinichi Noto; Takashi Fukuda; Elly Stolk
Journal:  Med Decis Making       Date:  2021-03-23       Impact factor: 2.583

9.  'Like holding the axe on who should live or not': adolescents' and adults' perceptions of valuing children's health states using a standardised valuation protocol for the EQ-5D-Y-3L.

Authors:  Mimmi Åström; Helen Conte; Jenny Berg; Kristina Burström
Journal:  Qual Life Res       Date:  2022-02-24       Impact factor: 3.440

10.  Objective Assessment of Postoperative Morbidity After Breast Cancer Treatments with Wearable Activity Monitors: The "BRACELET" Study.

Authors:  Nur Amalina Che Bakri; Richard M Kwasnicki; Kieran Dhillon; Naairah Khan; Omar Ghandour; Alexander Cairns; Ara Darzi; Daniel R Leff
Journal:  Ann Surg Oncol       Date:  2021-07-26       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.